Gemini Financial Statements From 2010 to 2024
| GMTXDelisted Stock | USD 17.95 0.05 0.28% |
Check Gemini Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gemini main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Gemini financial statements analysis is a perfect complement when working with Gemini Therapeutics Valuation or Volatility modules.
Gemini |
Gemini Therapeutics Company Current Valuation Analysis
Gemini Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Gemini Therapeutics Current Valuation | (34.25 M) |
Most of Gemini Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gemini Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Gemini Therapeutics has a Current Valuation of (34.25 Million). This is 100.24% lower than that of the Healthcare sector and 100.74% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 100.21% higher than that of the company.
Gemini Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gemini Therapeutics's current stock value. Our valuation model uses many indicators to compare Gemini Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gemini Therapeutics competition to find correlations between indicators driving Gemini Therapeutics's intrinsic value. More Info.Gemini Therapeutics is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Gemini Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Gemini Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gemini Therapeutics' earnings, one of the primary drivers of an investment's value.About Gemini Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Gemini Therapeutics income statement, its balance sheet, and the statement of cash flows. Gemini Therapeutics investors use historical funamental indicators, such as Gemini Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Gemini Therapeutics investors may use each financial statement separately, they are all related. The changes in Gemini Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Gemini Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Gemini Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Gemini Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration . Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Gemini Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Gemini Stock
If you are still planning to invest in Gemini Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gemini Therapeutics' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets |